ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high.

NEW PARTNERSHIP WITH ACCORD FOR COMMERCIALIZATION OF TEPADINA®

We are proud to announce that on November 19, 2019 ADIENNE Pharma & Biotech SA and ACCORD HEALTHCARE Ltd have entered into an exclusive licensing and distribution agreement for the commercialization of TEPADINA® 15 mg and 100 mg lyophilized powder for injections.

Click HERE to read the full news.

ADIENNE GRANTED AIFA MANUFACTURING AUTHORIZATION 

Following inspection performed by AIFA (Agenzia Italiana del Farmaco) last December, on February 12, 2019 ADIENNE has been granted the authorization n. aM - 12/2019 for the manufacturing of investigational biotech products at its plant located in Caponago (Italy).